Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, Jin Joo | - |
dc.contributor.author | Kang, Young Sun | - |
dc.contributor.author | Hyun, Young Youl | - |
dc.contributor.author | Han, Sang Youb | - |
dc.contributor.author | Jee, Yi Hwa | - |
dc.contributor.author | Han, Kum Hyun | - |
dc.contributor.author | Han, Jee Young | - |
dc.contributor.author | Cha, Dae Ryong | - |
dc.date.accessioned | 2021-09-06T00:31:29Z | - |
dc.date.available | 2021-09-06T00:31:29Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-06-21 | - |
dc.identifier.issn | 0024-3205 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/102943 | - |
dc.description.abstract | Aims: Sulodexide is a promising therapeutic drug for the management of diabetic nephropathy. Although sulodexide has demonstrated a renoprotective effect through its ability to restore glomerular ionic permselectivity, the exact mechanism is still not clear. We investigated the effects of long-term sulodexide treatment on diabetic nephropathy in Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats. Main methods: Diabetic rats were treated with or without sulodexide at 10 mg/kg/day in the drinking water for nine months. Renal morphology and changes in VEGF and p38 mitogen-activated protein kinase (p38 MAPK), urinary levels of albumin (UAE) and urinary VEGF excretion were determined. To define the direct effects of sulodexide, we performed an in vitro experiment using podocytes. Key findings: UAE was significantly higher in OLETF rats than in control LETO rats, and the sulodexide group showed significantly decreased UAE after six months of treatment. Interestingly, urinary VEGF levels were also significantly decreased in the sulodexide-treated group. In accordance with UAE and urinary VEGF changes, the renal expression of profibrotic molecules was significantly decreased after sulodexide treatment. In addition, the activation of p38 MAPK, assessed by measuring the level of phospho-specific p38 MAPK, increased in diabetic renal tissues and was markedly suppressed by sulodexide treatment. In cultured podocytes, sulodexide treatment significantly decreased high glucose-induced p38 MAPK activation and VEGF synthesis. Significance: Sulodexide directly suppresses VEGF synthesis through the p38 MAPK pathway in podocytes, and these results suggest that sulodexide may provide renoprotection via suppression of renal VEGF synthesis independently of glomerular basement membrane ionic permselectivity in type 2 diabetic rats. (C) 2013 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | PERMEABILITY FACTOR | - |
dc.subject | NEPHROPATHY | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | DYSFUNCTION | - |
dc.subject | EXPRESSION | - |
dc.subject | PODOCYTES | - |
dc.subject | PATHWAYS | - |
dc.subject | GLUCOSE | - |
dc.subject | VEGF | - |
dc.subject | CELL | - |
dc.title | Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, Jin Joo | - |
dc.contributor.affiliatedAuthor | Cha, Dae Ryong | - |
dc.identifier.doi | 10.1016/j.lfs.2013.04.008 | - |
dc.identifier.scopusid | 2-s2.0-84878568490 | - |
dc.identifier.wosid | 000339259100003 | - |
dc.identifier.bibliographicCitation | LIFE SCIENCES, v.92, no.23, pp.1118 - 1124 | - |
dc.relation.isPartOf | LIFE SCIENCES | - |
dc.citation.title | LIFE SCIENCES | - |
dc.citation.volume | 92 | - |
dc.citation.number | 23 | - |
dc.citation.startPage | 1118 | - |
dc.citation.endPage | 1124 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PERMEABILITY FACTOR | - |
dc.subject.keywordPlus | NEPHROPATHY | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | DYSFUNCTION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PODOCYTES | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | VEGF | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordAuthor | Diabetic nephropathy | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.